Medical School · Year 2 · Immunology · includes a quiz and discussion video

Lecture 4: T Cells and Cell-Mediated Immunity

Unit 2.7: Immunology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe T cell development and selection in the thymus
2. Explain the structure of the T cell receptor and its signaling
3. Describe CD4+ T helper cell subsets and their functions
4. Explain CD8+ cytotoxic T cell mechanisms
5. Describe T cell activation and effector functions
6. Explain regulatory T cells and immune tolerance

Lecture Outline

I. T Cell Development in the Thymus

T cell development occurs exclusively in the thymus, a specialized primary lymphoid organ where bone marrow-derived progenitors undergo a complex maturation process that generates a diverse repertoire of functional T cells while eliminating those that are either non-functional or potentially dangerous to the host. The thymus provides a unique microenvironment consisting of cortical and medullary regions populated by specialized thymic epithelial cells, dendritic cells, and macrophages that guide developing T cells through sequential developmental stages. This process is essential for establishing cell-mediated immunity while simultaneously establishing central tolerance to self-antigens.

T cell development proceeds through distinct stages defined by expression of the coreceptors CD4 and CD8. Early thymocyte progenitors (ETPs) entering from the bone marrow lack both CD4 and CD8, defining them as double-negative (DN) cells. The DN stage is further subdivided into four sequential stages (DN1 through DN4) based on expression of CD44 and CD25. During DN2 and DN3 stages, TCRbeta chain gene rearrangement occurs through V-D-J recombination involving recombination-activating genes RAG1 and RAG2. Successful rearrangement produces a functional beta chain that pairs with a surrogate alpha chain (pre-Talpha) and CD3 signaling molecules to form the pre-T cell receptor.

The beta-selection checkpoint represents a critical quality control mechanism occurring at the DN3 to DN4 transition. Cells that successfully generate a functional TCRbeta chain receive survival and proliferation signals through the pre-TCR, allowing them to proceed to the double-positive (DP) stage characterized by expression of both CD4 and CD8. Cells failing to produce a functional beta chain undergo apoptosis. Following beta-selection, TCRalpha chain rearrangement occurs, which uses V-J recombination without a D segment, generating the complete alphabeta TCR that will determine the cell's antigen specificity. The TCRbeta locus resides on chromosome 7q34, while the TCRalpha locus is located on chromosome 14q11.

Positive and negative selection shape the T cell repertoire during the DP stage. Positive selection occurs in the thymic cortex, where DP thymocytes interact with MHC molecules expressed on cortical thymic epithelial cells. Cells whose TCRs bind self-MHC with weak to moderate affinity receive survival signals, while those failing to recognize MHC at all undergo death by neglect. The strength of TCR-MHC interaction also determines lineage commitment, with MHC class II recognition directing CD4 single-positive (SP) development and MHC class I recognition directing CD8 SP development. Negative selection occurs primarily in the thymic medulla, where medullary thymic epithelial cells express tissue-restricted antigens under control of the autoimmune regulator (AIRE) transcription factor. Thymocytes binding self-antigen-MHC complexes with high affinity are deleted by apoptosis, eliminating potentially autoreactive cells and establishing central tolerance.

<image> Panel A: Comprehensive diagram of thymic architecture showing the cortical region where positive selection occurs with cortical thymic epithelial cells (cTECs) presenting self-MHC molecules to double-positive thymocytes, and the medullary region where negative selection occurs with medullary thymic epithelial cells (mTECs) expressing AIRE and presenting tissue-specific antigens, with arrows indicating thymocyte migration patterns from cortex to medulla Panel B: Flowchart of T cell developmental stages showing progression from early thymic progenitor (ETP/DN1, CD4-CD8-) through DN2-DN4 stages with TCRbeta rearrangement, beta-selection checkpoint, double-positive stage (CD4+CD8+) with TCRalpha rearrangement, and finally single-positive (CD4+ or CD8+) mature T cells, with key surface markers and molecular events labeled at each stage Panel C: Illustration of positive and negative selection outcomes showing three fates: successful weak MHC recognition leading to survival and maturation (positive selection), no MHC recognition leading to death by neglect, and strong self-antigen recognition leading to clonal deletion (negative selection), with corresponding percentages of thymocytes undergoing each fate Panel D: Molecular diagram of AIRE function in medullary thymic epithelial cells showing AIRE transcription factor activating expression of genes for tissue-restricted antigens (insulin, thyroglobulin, myelin proteins), these proteins being processed and presented on MHC molecules, and interaction with developing thymocytes for negative selection </image>

II. T Cell Receptor Structure

The T cell receptor is a heterodimeric protein complex that recognizes peptide antigens presented in the context of major histocompatibility complex molecules, a fundamental feature distinguishing T cell recognition from the direct antigen binding characteristic of B cell receptors and antibodies. The vast majority of peripheral T cells express alphabeta TCRs, while a smaller population expresses gammadelta TCRs that recognize antigens through different mechanisms. The TCR does not function in isolation but rather operates as part of a larger signaling complex that includes the CD3 molecules and zeta chains required for signal transduction following antigen recognition.

The alphabeta TCR consists of two transmembrane glycoprotein chains, each containing variable and constant immunoglobulin-like domains. The variable regions of both chains contain complementarity-determining regions (CDRs) that form the antigen-binding site. CDR1 and CDR2 loops primarily contact the MHC molecule itself, while CDR3, located at the junction of V, D (for beta chain), and J gene segments, makes the most critical contacts with the bound peptide and is the primary determinant of antigen specificity. This arrangement ensures that T cells can only recognize antigens when properly presented by MHC molecules, a phenomenon termed MHC restriction. The diversity of the TCR repertoire is generated through somatic V(D)J recombination during thymic development, producing an estimated 10^15 to 10^18 potential specificities.

The CD3 complex associates with the TCR and provides the signaling machinery necessary for T cell activation. CD3 consists of four distinct polypeptides that form three dimers: CD3gamma-epsilon, CD3delta-epsilon, and the zeta-zeta homodimer. The cytoplasmic tails of CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs), which are phosphorylated by Src family kinases upon TCR engagement and serve as docking sites for downstream signaling molecules. The zeta chain contains three ITAMs, making it particularly important for signal amplification. Notably, the TCR alpha and beta chains themselves have very short cytoplasmic tails incapable of signaling, making the association with CD3 essential for T cell activation.

Coreceptors CD4 and CD8 enhance TCR signaling by binding to nonpolymorphic regions of MHC molecules and recruiting the Src family kinase Lck to the TCR-CD3 complex. CD4 is a single-chain molecule that binds to the beta2 domain of MHC class II molecules, while CD8 exists primarily as an alphabeta heterodimer that binds the alpha3 domain of MHC class I molecules. Both coreceptors associate with Lck through their cytoplasmic tails, positioning this kinase to phosphorylate CD3 ITAMs upon TCR engagement. This coreceptor function increases the sensitivity of antigen recognition approximately 100-fold. The coreceptor expression pattern also determines which MHC class restricts a given T cell: CD4+ T cells recognize peptide-MHC class II complexes and typically function as helper cells, while CD8+ T cells recognize peptide-MHC class I complexes and primarily function as cytotoxic effectors.

<image> Panel A: Structural diagram of the complete TCR-CD3 complex showing the alphabeta TCR heterodimer with variable and constant domains, associated CD3gamma-epsilon and CD3delta-epsilon heterodimers, and zeta-zeta homodimer, with ITAMs in cytoplasmic tails highlighted and Lck association with coreceptors indicated Panel B: Top-down view of TCR-peptide-MHC interaction showing CDR1 and CDR2 loops of both alpha and beta chains contacting the MHC alpha helices, while CDR3 loops extend into the peptide-binding groove to contact the presented peptide, with germline-encoded versus junctional diversity regions color-coded Panel C: Comparison diagram of TCR versus BCR characteristics showing TCR as membrane-bound only, monovalent, recognizing peptide-MHC without somatic hypermutation, versus BCR/antibody which can be secreted, is bivalent, recognizes native antigen directly, and undergoes somatic hypermutation Panel D: Illustration of coreceptor function showing CD4 binding to MHC class II beta2 domain and CD8 binding to MHC class I alpha3 domain, with Lck kinase associated with coreceptor cytoplasmic tails and positioned to phosphorylate CD3 ITAMs upon TCR engagement </image>

III. T Cell Activation

T cell activation requires the integration of multiple signals to ensure that responses are mounted only against appropriate targets and under appropriate circumstances. The two-signal model, now expanded to three signals, provides a framework for understanding how antigen-presenting cells control T cell responses. This multi-signal requirement prevents inappropriate activation against self-antigens presented in non-inflammatory contexts and ensures that T cell responses are properly tailored to the type of pathogen encountered. Failure to receive all required signals results in T cell anergy or deletion rather than productive activation.

Signal 1 is provided by TCR recognition of peptide-MHC complexes on the surface of antigen-presenting cells. This interaction must achieve a threshold affinity and duration to trigger downstream signaling cascades. Upon TCR engagement, Lck phosphorylates ITAMs on CD3 and zeta chains, creating docking sites for the zeta-chain-associated protein kinase 70 (ZAP-70). ZAP-70 is recruited to phosphorylated ITAMs through its tandem SH2 domains and is subsequently activated by Lck phosphorylation. Activated ZAP-70 phosphorylates adaptor proteins LAT and SLP-76, which serve as scaffolds for assembly of downstream signaling complexes that activate multiple pathways including phospholipase C-gamma (PLCgamma), the Ras-MAPK pathway, and the PI3K-Akt pathway.

Signal 2 consists of costimulatory interactions that amplify and sustain T cell activation initiated by TCR signaling. The prototypical costimulatory pathway involves CD28 on T cells binding to CD80 (B7-1) or CD86 (B7-2) on activated antigen-presenting cells. CD28 signaling enhances IL-2 production, promotes T cell survival through Bcl-xL induction, and stabilizes cytokine mRNAs for increased protein production. Without costimulation, TCR signaling alone induces a state of anergy characterized by inability to produce IL-2 and proliferate upon subsequent antigen encounter. This requirement for costimulation provides a safeguard against autoimmunity, as self-antigens encountered in non-inflammatory conditions are presented by APCs lacking costimulatory molecule expression.

The immunological synapse is a specialized structure formed at the interface between T cells and antigen-presenting cells that organizes signaling molecules for optimal activation. The synapse consists of concentric rings: the central supramolecular activation cluster (cSMAC) contains TCR-MHC complexes, CD3, CD28, and protein kinase C-theta (PKCtheta), while the peripheral SMAC (pSMAC) contains the integrin LFA-1 bound to ICAM-1, providing adhesion that stabilizes the interaction. The distal SMAC (dSMAC) contains large molecules like CD45 phosphatase that are excluded from signaling zones. TCR signaling activates three major transcription factor pathways: NFAT (nuclear factor of activated T cells) activated through calcium-calcineurin signaling drives IL-2 transcription, NF-kappaB promotes survival and proliferation, and AP-1 cooperates with NFAT for cytokine gene transcription. Signal 3, provided by cytokines from the APC, determines T helper cell differentiation fate.

<image> Panel A: Three-signal model diagram showing Signal 1 (TCR engaging peptide-MHC), Signal 2 (CD28 engaging CD80/CD86 costimulatory molecules), and Signal 3 (cytokines such as IL-12, IL-4, or IL-6 from the APC), with arrows indicating how each signal contributes to complete T cell activation, proliferation, and differentiation Panel B: TCR signaling cascade illustration showing Lck phosphorylation of CD3 ITAMs, ZAP-70 recruitment and activation, phosphorylation of LAT and SLP-76 adaptor proteins, and downstream activation of PLCgamma (leading to calcium flux and NFAT), Ras-MAPK (leading to AP-1), and PI3K-Akt (leading to survival and metabolism) Panel C: Immunological synapse structure viewed from the T cell side showing concentric organization with cSMAC (TCR, CD3, CD28, PKCtheta) in center, pSMAC (LFA-1/ICAM-1 adhesion ring) surrounding it, and dSMAC (CD45, large glycoproteins) at periphery, with functional significance of each zone indicated Panel D: Outcomes of different signal combinations showing full activation (Signal 1 + 2 + 3) leading to proliferation and differentiation, anergy (Signal 1 alone) leading to unresponsiveness, and proper differentiation (all signals with specific cytokines) directing Th1, Th2, or Th17 fates </image>

IV. CD4+ T Helper Subsets

CD4+ T helper cells orchestrate immune responses by producing cytokines that activate and direct other immune cells, and the discovery that these cells differentiate into distinct functional subsets with characteristic cytokine profiles revolutionized our understanding of adaptive immunity. T helper cell differentiation is driven by cytokines present during initial activation, which activate specific transcription factors that establish stable gene expression programs. Each subset produces a signature set of cytokines that provides optimal defense against particular pathogen types while potentially contributing to immunopathology when dysregulated.

Th1 cells are characterized by expression of the master transcription factor T-bet and production of interferon-gamma (IFN-gamma) as their signature cytokine. Th1 differentiation is driven by IL-12 produced by dendritic cells and macrophages in response to intracellular pathogens, and by IFN-gamma itself in a positive feedback loop. The primary function of Th1 cells is activation of macrophages for enhanced killing of intracellular pathogens, including bacteria such as Mycobacterium tuberculosis and parasites like Leishmania. IFN-gamma upregulates MHC class II expression on macrophages, enhances production of reactive oxygen and nitrogen species, and promotes phagolysosome fusion. Th1 cells also provide help for production of opsonizing and complement-fixing antibody isotypes. Excessive or inappropriate Th1 responses contribute to autoimmune diseases including multiple sclerosis, type 1 diabetes, and rheumatoid arthritis.

Th2 cells express the master transcription factor GATA-3 and produce IL-4, IL-5, and IL-13 as their signature cytokines. Th2 differentiation is driven by IL-4, though the initial source of IL-4 that initiates Th2 responses remains debated, with basophils, mast cells, and NKT cells all proposed as candidates. Th2 responses are critical for defense against extracellular parasites, particularly helminths, and act primarily by activating eosinophils (through IL-5), promoting mucus production and smooth muscle contractility (through IL-13), and inducing B cell class switching to IgE (through IL-4). The IgE-mast cell-eosinophil axis mobilized by Th2 cells is effective against large parasites that cannot be phagocytosed. However, Th2 responses against innocuous environmental antigens underlie allergic diseases including asthma, allergic rhinitis, and atopic dermatitis.

Th17 cells express the master transcription factor RORgammat and produce IL-17A, IL-17F, and IL-22. Th17 differentiation requires TGF-beta plus IL-6 for initiation and IL-23 for maintenance and expansion. These cells provide critical defense against extracellular bacteria and fungi at mucosal surfaces by recruiting neutrophils through IL-17-induced chemokine production by epithelial cells and by enhancing epithelial barrier function through IL-22. Th17 responses are particularly important for immunity against Candida and Staphylococcus at mucosal sites. However, Th17 cells also drive pathology in numerous autoimmune and inflammatory diseases, including psoriasis, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis, making IL-17 and IL-23 important therapeutic targets.

<image> Panel A: Comprehensive diagram of Th1 differentiation and function showing IL-12 and IFN-gamma inducing T-bet expression, T-bet driving IFN-gamma production, and IFN-gamma activating macrophages for enhanced intracellular killing, promoting opsonizing antibody production, and contributing to autoimmunity when excessive Panel B: Th2 differentiation and function diagram showing IL-4 inducing GATA-3, GATA-3 driving IL-4, IL-5, and IL-13 production, with downstream effects including B cell class switch to IgE, eosinophil activation, goblet cell hyperplasia, and smooth muscle contraction in the context of anti-helminth immunity and allergic disease Panel C: Th17 differentiation and function showing TGF-beta plus IL-6 inducing RORgammat, IL-23 maintaining the phenotype, and IL-17A/IL-17F and IL-22 production leading to neutrophil recruitment, antimicrobial peptide production, and epithelial barrier enhancement for anti-fungal and anti-bacterial immunity Panel D: Comparative summary of all major CD4+ T helper subsets in a single visual showing Th1, Th2, Th17, Tfh, and Treg with their inducing cytokines, master transcription factors, signature cytokines, primary functions, and disease associations when dysregulated </image>

V. T Follicular Helper Cells

T follicular helper (Tfh) cells represent a specialized CD4+ T cell subset that provides essential help to B cells in germinal centers, making them critical for the generation of high-affinity antibodies and long-lived plasma cells and memory B cells. Unlike other T helper subsets that function primarily in peripheral tissues, Tfh cells reside in B cell follicles of secondary lymphoid organs, where they engage in cognate interactions with antigen-specific B cells. The importance of Tfh cells is underscored by immunodeficiency syndromes resulting from their absence or dysfunction and by their dysregulation in autoimmune diseases characterized by pathogenic autoantibody production.

Tfh cell differentiation begins when naive CD4+ T cells are activated by dendritic cells presenting antigen in the T cell zone of lymph nodes or spleen. IL-6 and IL-21 promote expression of the master transcription factor Bcl-6, which establishes the Tfh program while repressing alternative T helper fates. Developing Tfh cells upregulate CXCR5, the receptor for the B cell zone chemokine CXCL13, allowing migration to the T-B border and subsequently into B cell follicles. Tfh cells are characterized by high expression of several molecules critical for B cell help: ICOS, which provides sustained costimulation for B cell activation; PD-1, which despite being an inhibitory receptor is essential for proper Tfh function; and CD40L, which delivers survival and activation signals to B cells through CD40.

Within germinal centers, Tfh cells occupy the light zone where they provide selection signals to B cells that have undergone somatic hypermutation in the dark zone. B cells present antigen captured through their surface immunoglobulin to Tfh cells, and those presenting antigen most effectively (reflecting higher affinity BCRs) receive the strongest helper signals. This competitive process drives affinity maturation by selecting B cells with the highest affinity for antigen. Tfh cells deliver help primarily through CD40L engagement of CD40 on B cells and through cytokine production, particularly IL-21, which promotes plasma cell differentiation and class-switch recombination, and IL-4, which directs class switching to IgG1 and IgE. The limited number of Tfh cells in each germinal center creates the competitive environment necessary for selection.

Clinical relevance of Tfh cells spans immunodeficiency, autoimmunity, and vaccination. ICOS deficiency results in common variable immunodeficiency with absent germinal centers and impaired antibody responses. Conversely, excessive Tfh activity contributes to autoimmune diseases characterized by pathogenic autoantibodies, with expanded circulating Tfh-like cells observed in systemic lupus erythematosus and correlating with disease activity. HIV preferentially infects Tfh cells due to their high CD4 expression and activated state, contributing to B cell dysfunction in AIDS. Understanding Tfh biology is crucial for vaccine development, as most successful vaccines work by inducing antibody responses that depend on Tfh-mediated germinal center reactions. Adjuvant strategies aimed at optimizing Tfh responses represent an active area of vaccine research.

<image> Panel A: Tfh cell differentiation journey showing initial activation by dendritic cells in the T cell zone, IL-6 and IL-21-driven Bcl-6 expression, CXCR5 upregulation, migration to the T-B border, and entry into B cell follicles, with key molecular markers (ICOS, PD-1, CXCR5, Bcl-6) indicated at each stage Panel B: Germinal center anatomy showing dark zone (B cell proliferation and somatic hypermutation) and light zone (Tfh-mediated selection), with Tfh cells providing CD40L and IL-21 signals to B cells presenting antigen, and the competitive selection process favoring high-affinity B cell clones Panel C: Molecular interactions between Tfh cells and B cells showing TCR-peptide-MHC II engagement, CD40L-CD40 costimulation essential for B cell survival, ICOS-ICOSL sustaining the interaction, and cytokine delivery (IL-21, IL-4) directing B cell differentiation and class switching Panel D: Clinical implications of Tfh biology showing ICOS deficiency causing CVID with absent germinal centers, excessive Tfh activity in SLE driving autoantibody production, HIV infection of Tfh cells, and vaccine strategies targeting Tfh induction for optimal antibody responses </image>

VI. CD8+ Cytotoxic T Cells

CD8+ cytotoxic T lymphocytes (CTLs) are the primary effector cells responsible for directly killing virus-infected cells and tumor cells, making them essential for antiviral immunity and cancer immunosurveillance. Unlike CD4+ T cells that function primarily through cytokine production, CTLs directly eliminate target cells through delivery of lethal signals. CTL responses are tightly regulated to prevent inappropriate tissue damage, requiring both strong TCR signals and proper licensing, typically through CD4+ T cell help, for optimal activation and memory generation.

Naive CD8+ T cells circulate through secondary lymphoid organs where they survey dendritic cells for cognate antigen presented on MHC class I molecules. Activation requires the same three-signal paradigm as CD4+ T cells: antigen recognition (signal 1), costimulation (signal 2), and cytokine support (signal 3). IL-12 and type I interferons provide particularly important signal 3 cytokines for CTL development. Additionally, dendritic cell licensing by CD4+ T helper cells, mediated through CD40L-CD40 interactions, optimizes CTL priming by enhancing dendritic cell costimulatory molecule expression and cytokine production. This help requirement links CTL responses to CD4+ T cell activation and provides an additional checkpoint preventing inappropriate cytotoxic responses.

CTLs employ two principal mechanisms for target cell killing: the perforin-granzyme pathway and the death receptor pathway. The perforin-granzyme pathway involves directed secretion of specialized cytotoxic granules toward the target cell following formation of an immunological synapse. Perforin, a pore-forming protein related to complement component C9, facilitates entry of granzymes into the target cell cytoplasm. Granzyme B, the most important effector, cleaves and activates caspases, initiating the apoptotic cascade, and can also directly cleave caspase substrates. The death receptor pathway involves CTL expression of Fas ligand (FasL), which engages Fas (CD95) on target cells, triggering caspase-8 activation and apoptosis. Serial killing allows a single CTL to eliminate multiple targets in succession by recycling cytotoxic machinery.

CTLs recognize targets through detection of foreign peptides presented on MHC class I molecules, which are expressed by virtually all nucleated cells. Virus-infected cells present viral peptides derived from proteins synthesized in the cytoplasm, flagging them for CTL-mediated destruction. Tumor cells may present mutant self-peptides (neoantigens) or overexpressed normal proteins. CTLs also produce cytokines, particularly IFN-gamma and TNF-alpha, that contribute to pathogen control through non-cytolytic mechanisms and activate macrophages. Importantly, CTLs cannot recognize targets that have lost MHC class I expression, a common immune evasion strategy employed by viruses and tumors. NK cells complement CTL function by detecting and eliminating MHC class I-negative targets through "missing self" recognition.

<image> Panel A: CTL activation process showing naive CD8+ T cell encountering antigen-presenting dendritic cell, three-signal requirement (TCR engagement, CD28-CD80/86 costimulation, IL-12/type I IFN cytokines), CD4+ T cell help through DC licensing via CD40L-CD40, and resulting clonal expansion into armed effector CTLs Panel B: Perforin-granzyme killing mechanism showing immunological synapse formation between CTL and target cell, directed granule secretion toward the synapse, perforin insertion into target membrane and pore formation, granzyme B entry and caspase activation leading to target cell apoptosis Panel C: Comparison of perforin-granzyme and death receptor pathways showing perforin-mediated granzyme delivery activating intrinsic apoptosis pathway, and FasL-Fas interaction activating extrinsic apoptosis pathway through caspase-8, both converging on caspase-3 and apoptotic cell death Panel D: Serial killing diagram showing single CTL sequentially engaging and killing multiple target cells, with granule regeneration between kills, demonstrating the efficiency of CTL-mediated elimination of infected or transformed cells </image>

VII. T Cell Memory

Immunological memory is a defining feature of adaptive immunity, enabling faster and more effective responses upon re-encounter with previously experienced pathogens. Following resolution of an infection, most effector T cells die through apoptosis, but a small fraction differentiate into long-lived memory cells that persist for years to decades. Memory T cells are distinguished from naive cells by their lower activation threshold, enhanced effector capacity, and ability to mount rapid recall responses without requiring the full priming process that characterizes primary responses. Understanding memory T cell biology is essential for rational vaccine design.

Memory T cells comprise several distinct subsets defined by their homing properties, effector functions, and self-renewal capacity. Central memory T cells (Tcm) express lymph node homing receptors CCR7 and CD62L, allowing them to recirculate through secondary lymphoid organs similar to naive cells. Tcm have high proliferative capacity and self-renewal ability but require re-stimulation to acquire effector functions. Effector memory T cells (Tem) lack CCR7 and CD62L and instead home to peripheral tissues, where they provide rapid effector function upon antigen encounter without requiring extensive proliferation. Tissue-resident memory T cells (Trm) permanently reside in peripheral tissues, particularly at barrier sites like skin, gut, and lung, expressing retention markers CD103 and CD69. Trm provide immediate frontline defense at sites of pathogen entry. Stem cell memory T cells (Tscm) represent the least differentiated memory subset, with superior self-renewal capacity and the ability to give rise to all other memory subsets.

Memory T cells differ fundamentally from naive cells in their activation requirements and kinetics. While naive T cells require strong costimulation and take days to develop effector function, memory cells respond within hours and can be activated with minimal costimulation. Memory cells maintain elevated expression of anti-apoptotic molecules and metabolic programs that support rapid proliferation. The enhanced responsiveness of memory cells reflects epigenetic changes established during initial activation that poise effector genes for rapid transcription. Memory CD8+ T cells are particularly important for protection against intracellular pathogens, as their rapid cytotoxic response can eliminate infected cells before viral replication establishes productive infection.

Memory T cell maintenance requires cytokine signals, particularly IL-7 and IL-15, which promote survival and homeostatic proliferation. IL-7 supports survival of both CD4+ and CD8+ memory cells, while IL-15 is particularly important for CD8+ memory maintenance and can drive proliferation. Importantly, antigen persistence is not required for memory maintenance, though this remains somewhat controversial and may differ between experimental systems. Clinical applications of memory T cell biology include vaccine design aimed at generating durable memory responses, adoptive cell therapy expanding tumor-specific memory cells, and understanding memory cell contributions to chronic inflammatory diseases. In transplantation, pre-existing memory T cells reactive against donor alloantigens pose significant barriers to tolerance induction.

<image> Panel A: Differentiation model of memory T cell subsets showing naive T cell activation, effector phase with clonal expansion, contraction with most cells dying, and memory formation, with branches showing differentiation into Tscm, Tcm, Tem, and Trm subsets, arranged by progressive differentiation and tissue distribution Panel B: Comparison of memory T cell subsets showing Tcm (CCR7+, CD62L+, lymphoid tissue, high proliferative capacity), Tem (CCR7-, CD62L-, peripheral tissues, immediate effector function), and Trm (CD103+, CD69+, tissue-resident, frontline defense), with functional characteristics and typical locations Panel C: Comparison of naive versus memory T cell responses showing primary response (slow, requires strong costimulation, peak at 7-14 days) versus secondary memory response (rapid, minimal costimulation needed, peak at 3-5 days), with magnitude and kinetics illustrated graphically Panel D: Memory maintenance mechanisms showing IL-7 signaling (via IL-7R/CD127) promoting survival through Bcl-2 upregulation, IL-15 signaling (via IL-15R) driving homeostatic proliferation particularly of CD8+ memory cells, and the antigen-independent nature of memory maintenance with periodic homeostatic turnover </image>

VIII. Regulatory T Cells

Regulatory T cells (Tregs) are a specialized CD4+ T cell subset dedicated to suppressing immune responses and maintaining self-tolerance. The importance of Tregs is dramatically illustrated by the fatal multi-organ autoimmune syndrome that develops in their absence, whether due to genetic deficiency in mice (scurfy mutation) or humans (IPEX syndrome). Tregs prevent autoimmunity, limit immunopathology during infections, and maintain immune homeostasis at mucosal surfaces. However, Treg-mediated suppression can also be detrimental when it inhibits beneficial immune responses, such as anti-tumor immunity.

Two main categories of Tregs exist based on their developmental origin. Thymic or natural Tregs (tTregs or nTregs) develop in the thymus from precursors recognizing self-antigen with intermediate affinity, representing a lineage diversion from conventional T cell development. These cells are characterized by stable expression of the transcription factor Foxp3, which is both necessary and sufficient for Treg development and function. Peripheral or induced Tregs (pTregs or iTregs) differentiate from conventional CD4+ T cells in peripheral tissues under tolerogenic conditions, particularly in the presence of TGF-beta and absence of inflammatory cytokines. A third population, type 1 regulatory cells (Tr1), produces IL-10 but does not express Foxp3 and arises through distinct mechanisms. The relative contributions of thymic versus peripherally-derived Tregs to tolerance maintenance in different tissues remains an active research area.

Tregs employ multiple suppressive mechanisms that can be categorized into those affecting antigen-presenting cells and those directly affecting effector T cells. Suppression through APCs includes CTLA-4-mediated downregulation or physical removal (transendocytosis) of CD80/CD86 costimulatory molecules from APC surfaces, rendering them unable to fully activate conventional T cells. Direct suppression of effector cells involves secretion of immunosuppressive cytokines, particularly IL-10, TGF-beta, and IL-35. Tregs constitutively express high-affinity IL-2 receptor (CD25), allowing them to consume IL-2 and deprive effector cells of this essential growth factor. Additional mechanisms include granzyme-mediated killing of effector cells, metabolic disruption through adenosine generation via CD39/CD73 ectoenzymes, and transfer of inhibitory cAMP through gap junctions.

Clinical applications of Treg biology span autoimmunity, transplantation, and cancer. In autoimmune diseases, Treg dysfunction or insufficiency contributes to pathology, and therapeutic strategies aim to expand or enhance Treg function. Low-dose IL-2 therapy selectively expands Tregs (which express high-affinity IL-2 receptors) and shows promise in conditions including type 1 diabetes and graft-versus-host disease. In transplantation, Treg infusion or in vivo expansion is being explored to induce tolerance and reduce immunosuppression requirements. Conversely, in cancer, Tregs infiltrating tumors suppress anti-tumor immunity, and strategies to deplete or inhibit tumor Tregs are being developed. Understanding the balance between immune protection and Treg-mediated suppression is critical for optimizing immunotherapy across disease contexts.

<image> Panel A: Treg development pathways showing thymic Treg development through intermediate-affinity self-antigen recognition leading to Foxp3 expression rather than negative selection, and peripheral Treg induction from naive CD4+ T cells under TGF-beta influence in tolerogenic conditions, with key transcription factors and cytokines indicated Panel B: Comprehensive diagram of Treg suppressive mechanisms including CTLA-4-mediated CD80/86 downregulation on APCs, IL-2 consumption depriving effector cells, secretion of IL-10, TGF-beta, and IL-35, granzyme-mediated killing, and adenosine generation through CD39/CD73 creating an immunosuppressive microenvironment Panel C: Foxp3 structure and function showing Foxp3 transcription factor domains, target genes (IL-2, CTLA-4, CD25, GITR), and consequences of FOXP3 mutations in IPEX syndrome including multi-organ autoimmunity (enteropathy, dermatitis, thyroiditis, type 1 diabetes) with early mortality Panel D: Clinical applications of Treg biology showing low-dose IL-2 therapy expanding Tregs in autoimmunity, Treg infusion for transplant tolerance, and anti-CTLA-4 or Treg depletion strategies to enhance anti-tumor immunity in cancer, illustrating how Treg manipulation can be beneficial or detrimental depending on context </image>

IX. T Cell Exhaustion

T cell exhaustion is a state of progressive dysfunction that develops when T cells experience chronic antigen stimulation, as occurs during persistent viral infections and cancer. Exhausted T cells exhibit hierarchical loss of effector functions, starting with reduced proliferative capacity and IL-2 production, progressing to decreased TNF-alpha secretion, and ultimately affecting cytotoxicity and IFN-gamma production in severely exhausted cells. This represents a distinct differentiation state rather than simply overwhelmed effector cells, involving specific transcriptional programs and epigenetic modifications. Understanding exhaustion has transformed cancer immunotherapy through the development of checkpoint blockade strategies that reinvigorate exhausted T cells.

The phenotype of exhausted T cells is characterized by high sustained expression of multiple inhibitory receptors, including PD-1 (programmed death-1), CTLA-4, LAG-3, TIM-3, and TIGIT. While these receptors are also transiently upregulated on activated effector T cells, their sustained high expression distinguishes exhaustion. PD-1 engagement by its ligands PD-L1 and PD-L2 on target cells or APCs delivers inhibitory signals that dampen T cell activation and effector function. In chronic viral infections, exhausted virus-specific CD8+ T cells express high PD-1 and fail to clear infection, but antibody-mediated PD-1 blockade can restore function and improve viral control. This fundamental observation laid the groundwork for cancer immunotherapy.

The development of exhaustion is driven by persistent antigen exposure in the context of chronic inflammation. Continuous TCR stimulation without resolution leads to progressive epigenetic changes that lock cells into the exhausted state. The transcription factor TOX is essential for exhaustion development, being induced by chronic TCR stimulation and enforcing the exhausted phenotype through epigenetic programming. Notably, exhaustion is not simply anergy or activation; exhausted cells maintain some function, continue to divide (though poorly), and crucially, their dysfunction can be partially reversed. However, severely exhausted cells harbor epigenetic modifications that limit the durability of reversal, representing a potential barrier to checkpoint blockade efficacy.

Checkpoint blockade immunotherapy represents the clinical application of exhaustion biology to cancer treatment. Antibodies blocking PD-1 (pembrolizumab, nivolumab), PD-L1 (atezolizumab, durvalumab), or CTLA-4 (ipilimumab) release inhibitory signals on exhausted tumor-infiltrating lymphocytes, reinvigorating anti-tumor responses. These therapies have achieved remarkable success in multiple cancer types, with durable responses in a subset of patients. Combination checkpoint blockade (anti-PD-1 plus anti-CTLA-4) increases response rates but also toxicity. Understanding the biology of exhaustion and reinvigoration is driving development of next-generation approaches, including targeting additional checkpoints (LAG-3, TIM-3, TIGIT), combining checkpoint blockade with other modalities, and developing strategies to prevent exhaustion from developing in adoptive cell therapies.

<image> Panel A: Progressive exhaustion model showing initial T cell activation producing functional effector cells, followed by persistent antigen exposure leading to early exhaustion (high PD-1, reduced IL-2), intermediate exhaustion (adding LAG-3, TIM-3, reduced TNF-alpha), and terminal exhaustion (adding TIGIT, reduced cytotoxicity and IFN-gamma), with corresponding functional decline illustrated Panel B: Inhibitory receptor signaling diagram showing PD-1 engaging PD-L1 on tumor cells, with downstream signaling through SHP-2 phosphatase that dephosphorylates TCR signaling components, attenuating activation signals, alongside similar inhibitory pathways from CTLA-4, LAG-3, and TIM-3 Panel C: Checkpoint blockade mechanism showing exhausted T cell in tumor microenvironment with high PD-1 expression being inhibited by PD-L1 on tumor cell, then anti-PD-1 antibody blocking this interaction and restoring T cell effector function, with reinvigorated T cell killing tumor cell Panel D: Clinical checkpoint blockade applications showing anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, their approved cancer indications, response rates, combination strategies, and immune-related adverse events as a consequence of releasing systemic T cell inhibition </image>

X. Clinical Applications

The understanding of T cell biology has enabled development of revolutionary immunotherapies that harness T cells to treat cancer and other diseases. Adoptive cell therapy involves isolating, manipulating, and expanding a patient's own T cells before reinfusion to target disease. These approaches have achieved remarkable successes particularly in hematologic malignancies and represent a rapidly evolving frontier of cancer treatment. The clinical application of T cell biology also extends to infectious diseases, autoimmunity, and transplantation.

Chimeric antigen receptor T cells (CAR-T) represent an engineered approach to generate tumor-specific T cells independent of MHC restriction. CAR constructs consist of an extracellular single-chain variable fragment (scFv) derived from a monoclonal antibody that provides antigen specificity, a transmembrane domain, and intracellular signaling domains including CD3zeta for activation and costimulatory domains (CD28 or 4-1BB) for sustained function. When expressed in patient T cells, CARs redirect these cells to recognize surface antigens on tumor cells. CD19-targeting CAR-T cells have achieved remarkable complete response rates in relapsed/refractory B-cell acute lymphoblastic leukemia and certain lymphomas, leading to multiple FDA approvals. BCMA-targeting CAR-T cells are approved for multiple myeloma. Solid tumor CAR-T development faces additional challenges including identifying tumor-specific targets, overcoming the immunosuppressive tumor microenvironment, and trafficking to tumor sites.

Tumor-infiltrating lymphocyte (TIL) therapy takes a different approach, expanding T cells that have naturally infiltrated a patient's tumor and therefore already recognize tumor antigens. After surgical resection, TILs are isolated, expanded to large numbers ex vivo (often billions of cells), and reinfused following lymphodepleting chemotherapy. This approach has shown durable responses in metastatic melanoma and has recently received FDA approval (lifileucel). TIL therapy has the advantage of preserving the polyclonal, tumor-specific repertoire naturally selected in vivo, potentially targeting multiple antigens including patient-specific neoantigens.

Complications of T cell therapies require careful management. Cytokine release syndrome (CRS) results from massive cytokine production by activated CAR-T cells and manifests as fever, hypotension, hypoxia, and in severe cases, multi-organ dysfunction. IL-6 is a key mediator, and the IL-6 receptor antagonist tocilizumab is effective treatment. Immune effector cell-associated neurotoxicity syndrome (ICANS) presents with confusion, aphasia, and in severe cases, cerebral edema; corticosteroids are the primary treatment. On-target, off-tumor toxicity occurs when CARs recognize antigens on normal tissues, exemplified by B cell aplasia with CD19 CAR-T therapy. Future directions include developing off-the-shelf allogeneic CAR-T products, armored CARs with enhanced function in the tumor microenvironment, and application to autoimmune diseases and infectious diseases.

<image> Panel A: CAR-T cell structure and generations showing first-generation CAR (scFv + CD3zeta), second-generation (adding CD28 or 4-1BB costimulatory domain), and third-generation (multiple costimulatory domains), with comparison of signaling strength, persistence, and clinical outcomes for each generation Panel B: CAR-T manufacturing and treatment process showing leukapheresis to collect patient T cells, genetic modification with CAR-encoding vector, ex vivo expansion, lymphodepleting chemotherapy, CAR-T infusion, and subsequent monitoring for response and toxicities Panel C: TIL therapy process showing surgical tumor resection, TIL isolation and expansion with IL-2, lymphodepletion conditioning, TIL infusion, and high-dose IL-2 support, with indication that this approach preserves natural polyclonal tumor-specific repertoire Panel D: Management of CAR-T toxicities showing CRS pathophysiology (massive cytokine release including IL-6) and treatment (tocilizumab, supportive care), and ICANS features (confusion, aphasia, seizures) and treatment (corticosteroids), with grading systems and intervention thresholds indicated </image>

Summary

• T cell development occurs in the thymus through DN to DP to SP stages with positive selection in cortex and negative selection (AIRE-dependent) in medulla establishing central tolerance
• TCR structure includes alphabeta heterodimer for peptide-MHC recognition plus CD3 complex providing signaling through ITAMs; coreceptors CD4 and CD8 enhance signaling and determine MHC restriction
• T cell activation requires three signals: TCR engagement, costimulation (CD28-CD80/86), and cytokines; the immunological synapse organizes this interaction
• Th1 cells (T-bet, IFN-gamma) activate macrophages against intracellular pathogens; Th2 cells (GATA-3, IL-4/5/13) direct anti-helminth responses and cause allergy; Th17 cells (RORgammat, IL-17) recruit neutrophils against extracellular bacteria and fungi
• Tfh cells (Bcl-6, CXCR5, IL-21) provide B cell help in germinal centers for affinity maturation and memory B cell generation
• CTLs kill targets via perforin-granzyme and Fas-FasL pathways; recognition requires peptide-MHC class I presentation
• Memory T cells include Tcm (lymphoid homing), Tem (tissue effector), and Trm (tissue-resident) subsets maintained by IL-7 and IL-15
• Tregs (Foxp3+) suppress immune responses through CTLA-4, IL-10, TGF-beta, and IL-2 consumption; deficiency causes IPEX syndrome
• T cell exhaustion develops during chronic antigen exposure with inhibitory receptor upregulation; checkpoint blockade (anti-PD-1, anti-CTLA-4) reinvigorates exhausted cells
• Clinical applications include CAR-T cells (CD19 for B-ALL and lymphoma, BCMA for myeloma) and TIL therapy; CRS and ICANS are important toxicities

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown